Paul G. Allen Frontiers Group [to 21 Sep 2019]
How the gut keeps time — and keeps us healthy
September 18, 2019
New study identifies brain-intestine circadian signals that could underlie health problems related to night shift work and poor sleep


BMGF – Gates Foundation [to 21 Sep 2019]
SEPTEMBER 17, 2019
Gates Foundation Report Spotlights New Data on Global Inequality, Calls to Prioritize Those Being Left Behind
New Sub-national Data Shows Surprising and Significant Progress, but Huge Gaps Remain, Driven by Gender and Geography


Bill & Melinda Gates Medical Research Institute [to 21 Sep 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 21 Sep 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
09.17.2019  |
CARB-X funds Procarta Biosystems to develop oligonucleotide-based antibiotics to combat life-threatening Gram-negative pathogens
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens. The new antibiotics are based on Procarta’s oligonucleotide antimicrobial platform. While still in preclinical development, if eventually approved for use in patients, Procarta’s PRO-202 antibiotics could be used to treat serious infections associated with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).


CEPI – Coalition for Epidemic Preparedness Innovations [to 21 Sep 2019]
A World at Risk: Global Preparedness Monitoring Board launches first annual report
18 Sep 2019
[See Milestones above for detail]


Clinton Health Access Initiative, Inc. (CHAI) [to 21 Sep 2019]
News & Press Releases
No new digest content identified.


EDCTP [to 21 Sep 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 21 Sep 2019]
Website not responding at inquiry


European Medicines Agency [to 21 Sep 2019]
News and press releases
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2019
CHMP, Last updated: 20/09/2019
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its September 2019 meeting.


European Vaccine Initiative [to 21 Sep 2019]
Latest news
No new digest content identified.


FDA [to 21 Sep 2019]
No new digest content identified.


Fondation Merieux [to 21 Sep 2019]
Mérieux Foundation event
7th Vaccine Acceptance Meeting
September 23 – 25, 2019 – Les Pensières Center for Global Health, Veyrier du Lac (France)
Early in 2019, the World Health Organization labelled reluctance to receive recommended vaccines – despite the availability of vaccination services – as one of the 10 most important threats to global health. At the same time, global headlines reported a 300% increase in measles cases worldwide, with many outbreaks directly linked to vaccine acceptance.


Gavi [to 21 Sep 2019]
Latest news
Gavi at the UNGA: People, planet and prosperity
19 September 2019
At the 74th United Nations General Assembly (UNGA), high-level government, UN and civil society representatives will gather in New York to assess progress on the Sustainable Development Goals, just as converging threats to the planet and people are calling for urgent attention.
[See Milestones above for Gavi high-level messages for UN General Assembly]


GHIT Fund [to 21 Sep 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.


Global Fund [to 21 Sep 2019]
News & Stories
Feature Story
Rwanda: A Nation Reborn
20 September 2019

Equal Salary Certification for the Global Fund
20 September 2019

Next Stop: Universal Health Coverage for all Africans
19 September 2019

Global Fund Partnership has Saved 32 Million Lives
19 September 2019
[See Milestones above for more detail]

Note on Global Fund Programmatic Results
19 September 2019

Data Explorer Enhancements: Results
19 September 2019

Sourcing & Management of Health Products
Opportunity for Evaluation of Diagnostic Products
17 September 2019


Hilleman Laboratories [to 21 Sep 2019]
No new digest content identified.


Human Vaccines Project [to 21 Sep 2019]
Press Releases
No new digest content identified.


IAVI [to 21 Sep 2019]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities (ICMRA)
Statements and Press Releases
No new digest content identified.



No new digest content identified.


IFRC [to 21 Sep 2019]
Selected Press Releases, Announcements
No new digest content identified.


IVAC [to 21 Sep 2019]
3 Things We Know About Vaccines in a Climate Change Future
By Molly Sauer Sep
1.  It’s likely more people will be affected by mosquito-borne diseases like dengue, yellow fever, and malaria
2.  Diarrheal diseases are likely to increase and some regions may see changes in seasonality
3.  Robust immunization programs are critical to support climate refugees and mitigate health security concerns…


IVI [to 21 Sep 2019]
Selected IVI News & Announcements
IVI co-organizes the 2019 International Vaccine Industry Forum with GIB
September 20, 2019, SEOUL, Korea — The International Vaccine Institute (IVI) joined forces with the Gyeongbuk Institute for Bioindustry (GIB) to organize the ‘2019 International Vaccine Industry Forum (IVIF 2019)’ in Andong, South Korea on September 19. The event was jointly hosted by Gyeongsangbuk-do Province and Andong City to help accelerate the development of the global vaccine industry and a vaccine industry cluster in the city.

The International Vaccine Industry Forum, which has convened every year since 2016, aims to share the latest vaccine industry trends and innovative technology advances, and explore development strategies for the vaccine industry. The event also offers a venue for discussion to promote Andong, home to IVI’s branch laboratory, vaccine companies and research facilities, as an emerging global vaccine hub.

Under the overall theme of “Development and Prospect of the Vaccine Industry through Public-Private Cooperation,” this year’s event entailed in-depth discussions about public and private partnership starting with a keynote speech, followed by two main sessions and a panel discussion…


JEE Alliance [to 21 Sep 2019]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 21 Sep 2019]
Working to turn the tide of hepatitis C in Karachi’s Machar Colony
Project Update 20 Sep 2019

Rohingya refugee crisis
Healthcare for struggling refugee communities in Malaysia
Project Update 20 Sep 2019

Beyond trauma injuries: One of Syria’s neglected health needs
Voices from the Field 17 Sep 2019


NIH [to 21 Sep 2019]
Selected News Releases
No new digest content identified.


PATH [to 21 Sep 2019]
Selected Announcements
No new digest content identified.


ProMED [Program for Monitoring Emerging Diseases] [to 21 Sep 2019]
International Society for Infectious Diseases
Selected Announcements/Posts
No new digest content identified.


Sabin Vaccine Institute [to 21 Sep 2019]
No new digest content identified.


UNAIDS [to 21 Sep 2019]
Selected Press Releases/Reports/Statements
20 September 2019
Reduce, reuse, recycle: young Ghanaians say yes to less

20 September 2019
How climate change is affecting people living with HIV

18 September 2019
Unwavering care for people who inject drugs on the streets of Glasgow

16 September 2019
Interview with UNAIDS PrEP expert Rosalind Coleman


UNICEF [to 21 Sep 2019]
Selected Statements, Press Releases, Reports
Press release
29 million babies born into conflict in 2018
UNICEF calls for increased support for parents forced to raise their babies and young children in conflict-affected areas

Press release
More women and children survive today than ever before – UN report
Despite progress, a pregnant woman or newborn dies somewhere in the world every 11 seconds


Vaccination Acceptance Research Network (VARN) [to 21 Sep 2019]
No new digest content identified.


Vaccine Confidence Project [to 21 Sep 2019]
Confidence Commentary:
First Global Vaccination Summit sounds the alarm on access and hesitancy
Posted on 15 Sep, 2019 Heidi Larson
One of the most important insights of the European Commission-hosted Vaccination Summit came from  Ethan Lindenberger, an 18-year old high school student who decided to get himself vaccinated  after his  mother chose not to vaccinate him. He spoke passionately  about the need to build bridges and recognize that,  “People who believe vaccine misinformation are not bad people… let’s not demonise them and build a wall, but rather extend a hand and build the bridges.”   – HL. 
Read full article here


Vaccine Education Center – Children’s Hospital of Philadelphia [to 21 Sep 2019]
No new digest content identified.


Wellcome Trust [to 21 Sep 2019]
Opinion | 18 September 2019
How do you get children from disadvantaged backgrounds engaged with science?
by Mat Hickman

Opinion | 16 September 2019
4 ways that PhD programmes are improving their training culture
by Anne-Marie Coriat
The new PhD programmes in science that we’re funding combine scientific excellence with a commitment to improving the working environment for trainees.


The Wistar Institute [to 21 Sep 2019]
Press Release Sep. 18, 2019
Identification of a Novel Regulator of Mitochondrial Cell Death Reveals a Promising Target for Cancer Therapy
PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein could represent a promising therapeutic target. They also found that expression of MFF is regulated by Myc, a ubiquitous mediator of cell proliferation that contributes to development of many cancer types. These results were published online in the journal EBioMedicine…


World Organisation for Animal Health (OIE) [to 21 Sep 2019]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 21 Sep 2019]
No new digest content identified.


BIO [to 21 Sep 2019]
Sep 20 2019
New Executive Order Critical to Protecting Patients and Public Health
President Trump has signed an executive order focused on spurring the development of new vaccine technologies, prioritizing the production of influenza vaccines and identifying strategies for communicating the importance of influenza vaccination.
[See Milestones above for full text]


DCVMN – Developing Country Vaccine Manufacturers Network [to 21 Sep 2019]
DCVMN 20th Annual General Meeting
21 October 2019 to 23 October 2019
Rio de Janeiro / Brazil


IFPMA [to 21 Sep 2019]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 21 Sep 2019]
Selected Press Releases, Statements
Press Release
PhRMA Names Lori Reilly Chief Operating Officer
Reilly to Lead Federal, State and International Advocacy and Alliance Development
Washington, D.C. (September 17, 2019) — The Pharmaceutical Research and Manufacturers of America (PhRMA) today named Lori M. Reilly, Esq. as chief operating officer (COO), a new position within PhRMA. Reilly has been at PhRMA for nearly 20 years, most recently serving as executive vice president of policy, research and membership.
In this newly created role, Reilly will provide executive level management, leadership and strategic direction to PhRMA and oversee the association’s federal, state and international government affairs and alliance development…


Industry Watch [to 21 Sep 2019]
Selected Announcements
:: FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
Merck Continues to Expand Investigational Supply to Support International Ebola Outbreak Response
September 17, 2019
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted priority review for Merck’s investigational Ebola vaccine (V920), under review for the prevention of disease caused by the Ebola Zaire virus. The Prescription Drug User Fee Act (PDUFA), or target action date, is set for March 14, 2020. In July 2016, the FDA granted Breakthrough Therapy Designation to V920.
“Merck has worked with government partners and the global health community to accelerate development of our investigational V920 Ebola vaccine. FDA’s priority review designation underscores our long-standing partnership with the U.S. government toward its development and licensure,” said Dr. Paula Annunziato, vice president, Merck Research Laboratories. “A top priority for us remains achieving registration of V920 and regulatory approval of our German manufacturing site, so that licensed supply can be produced over time to support global public health preparedness and health security objectives. We look forward to continuing to work with the FDA throughout the review process.” …